Tyrosine kinase inhibitors (TKI): targets and indications

Evidence-based neurology checklist on tyrosine kinase inhibitors (tki): targets and indications: Targets Anaplastic lymphocyte kinase (ALK) Bruton's tyrosine kinase (BTK) Epidermal growth factor receptor (EGFR) Fibroblast growth factor receptor (FGFR) Human epidermal growth factor receptor 2…

Targets

  • Anaplastic lymphocyte kinase (ALK)
  • Bruton's tyrosine kinase (BTK)
  • Epidermal growth factor receptor (EGFR)
  • Fibroblast growth factor receptor (FGFR)
  • Human epidermal growth factor receptor 2 (HER2)
  • Mesenchymal-epithelial transition factor (MET)
  • Mitogen-activated protein kinase (MEK)
  • Platelet-derived growth factor receptor (PDGFR)
  • Proto oncogene receptor (KIT)
  • Rearranged during transfection (RET)
  • ROS proto-oncogene 1 (ROS1)
  • SRC proto-oncogene (SRC)
  • Tropomyosin receptor kinase (TRK)
  • Vascular endothelial growth factor receptor (VEGFR)

Indications

References

  1. Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 2018; 17:36.
  2. Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020; 13:143.

Related checklists

Loading...